FDA approves sotagliflozin (SGLT1 & 2 inhibitor) to reduce risk for HF death, hospitalization

The FDA has approved sotagliflozin, an SGLT1/SGLT2 inhibitor, for reduction of risk for death, HF hospitalization and urgent HF visits in patients with HF and in those with certain CV risk factors, Lexicon Pharmaceuticals announced.

The Company: https://www.lexpharma.com/

Company Press release:



Ping me when this gets available on india-mart…

1 Like